Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22967056 | 0.98 | ADORA2A (0.39) | ADORA2AADORA2BKMT2AMEN1L3MBTL1 | |
| SCHEMBL22967264 | 0.91 | LMNA (0.33) | ADORA2AADORA2BKMT2AMEN1LMNA | |
| SCHEMBL22967215 | 0.91 | ROCK2 (0.41) | ADORA2AADORA2BLMNAHTTPDE3B | |
| SCHEMBL22967259 | 0.91 | ROCK2 (0.41) | ADORA2AADORA2BLMNAHTTPDE3B | |
| SCHEMBL22967055 | 0.86 | CDK4 (0.45) | KMT2AMEN1L3MBTL1ALDH1A1LMNA | |
| SCHEMBL22967237 | 0.82 | CYP1A2 (0.43) | ADORA2AADORA2BALDH1A1SMN1; SMN2 | |
| SCHEMBL22967263 | 0.82 | MAPT (0.32) | ADORA2AADORA2BKMT2AL3MBTL1LMNA | |
| SCHEMBL21217525 | 0.80 | ROCK2 (0.58) | KMT2AMEN1 | |
| SCHEMBL22967260 | 0.80 | ADORA2B (0.35) | ADORA2AADORA2BLMNA | |
| SCHEMBL24094162 | 0.80 | CTDSP1 (0.39) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4026834-A1 | HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | Redx Pharma Plc (GB) | 2022-07-13 | — | — | EP | disclosed |
| US-20210038606-A1 | Modulators of Rho-associated Protein Kinase | REDX PHARMA LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210038606-A1 | Modulators of Rho-associated Protein Kinase | ROCK2, ROCK1, RHOA | ADORA2A 2258/4885ADORA2B 3452/4885KMT2A 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.